View Future GrowthPYC Therapeutics 過去の業績過去 基準チェック /06PYC Therapeuticsの収益は年間平均-29.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間34.1% 28.2%割合で 増加しています。主要情報-29.23%収益成長率-17.24%EPS成長率Biotechs 業界の成長17.04%収益成長率28.17%株主資本利益率-32.76%ネット・マージン-231.33%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 08Pyc Therapeutics Limited Announces Appointment of Thomas Ulmer as Chief Financial OfficerPYC Therapeutics Limited announced the appointment of Mr. Thomas Ulmer as the Company’s Chief Financial Officer. Mr. Ulmer has 20 years of international leadership experience across biotechnology, pharmaceuticals and healthcare. Most recently he served as Chief Financial Officer of Cell Therapies Pty Ltd. and previously as Chief Executive Officer of PKG Health. Prior to this, Mr. Ulmer was Chief Financial Officer of Immatics N.V. (NASDAQ: IMTX), where he played a key role in the company's NASDAQ listing and establishment as a US-listed biotechnology company. Earlier in his career he held senior finance leadership roles with Allergopharma and Merck Group. Mr. Ulmer holds an MBA from Justus Liebig University, Germany, and is a Fellow of CPA Australia.お知らせ • Jun 15PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026PYC Therapeutics Limited advised that Mr. Stephen Ledger and Mr. Jonathan Riley had been appointed as joint Company Secretaries of the Company effective June 15, 2026. Mr. Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group. Mr. Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr. Riley held a senior legal role at CSL Limited in Melbourne. For the purposes of ASX Listing Rule 12.6, Mr. Ledger will be responsible for communications with ASX in relation to Listing Rule matters. Mr. Daniel Coletta has resigned as Company Secretary effective June 15, 2026.お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listingお知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australiaお知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights Offering収支内訳PYC Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PYCX.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 2521-4886530 Sep 2522-4976830 Jun 2523-5077031 Mar 2524-4967031 Dec 2425-4857030 Sep 2424-4356330 Jun 2422-3855631 Mar 2422-3044831 Dec 2321-2243930 Sep 2319-2243730 Jun 2316-2343531 Mar 2315-2353431 Dec 2214-2463330 Sep 2215-1962830 Jun 2216-1462431 Mar 2213-1572131 Dec 219-1781830 Sep 216-1781630 Jun 213-1881431 Mar 213-1561231 Dec 202-1241130 Sep 202-94830 Jun 202-74631 Mar 201-64331 Dec 190-54030 Sep 190-53030 Jun 190-42031 Mar 190-41031 Dec 180-51030 Sep 180-62030 Jun 180-73031 Mar 180-63031 Dec 170-54030 Sep 171-33030 Jun 173-22031 Mar 173-32031 Dec 163-42030 Sep 161-41030 Jun 160-41031 Mar 160-42031 Dec 150-42030 Sep 150-320質の高い収益: PYCX.Fは現在利益が出ていません。利益率の向上: PYCX.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PYCX.Fは利益が出ておらず、過去 5 年間で損失は年間29.2%の割合で増加しています。成長の加速: PYCX.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PYCX.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。株主資本利益率高いROE: PYCX.Fは現在利益が出ていないため、自己資本利益率 ( -32.76% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/22 15:11終値2026/08/19 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PYC Therapeutics Limited 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterDavid MartinBloom Burton & Co.4 その他のアナリストを表示
お知らせ • Jul 08Pyc Therapeutics Limited Announces Appointment of Thomas Ulmer as Chief Financial OfficerPYC Therapeutics Limited announced the appointment of Mr. Thomas Ulmer as the Company’s Chief Financial Officer. Mr. Ulmer has 20 years of international leadership experience across biotechnology, pharmaceuticals and healthcare. Most recently he served as Chief Financial Officer of Cell Therapies Pty Ltd. and previously as Chief Executive Officer of PKG Health. Prior to this, Mr. Ulmer was Chief Financial Officer of Immatics N.V. (NASDAQ: IMTX), where he played a key role in the company's NASDAQ listing and establishment as a US-listed biotechnology company. Earlier in his career he held senior finance leadership roles with Allergopharma and Merck Group. Mr. Ulmer holds an MBA from Justus Liebig University, Germany, and is a Fellow of CPA Australia.
お知らせ • Jun 15PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026PYC Therapeutics Limited advised that Mr. Stephen Ledger and Mr. Jonathan Riley had been appointed as joint Company Secretaries of the Company effective June 15, 2026. Mr. Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group. Mr. Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr. Riley held a senior legal role at CSL Limited in Melbourne. For the purposes of ASX Listing Rule 12.6, Mr. Ledger will be responsible for communications with ASX in relation to Listing Rule matters. Mr. Daniel Coletta has resigned as Company Secretary effective June 15, 2026.
お知らせ • Mar 10PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 272,740,242 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,197,631 Price\Range: AUD 1.5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,573,060 Price\Range: AUD 1.5 Discount Per Security: AUD 0.075 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Feb 04PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 02+ 1 more updatePYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 128.233601 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 85,489,067 Price\Range: AUD 1.5 Discount Per Security: AUD 0.09 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 18PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia
お知らせ • Sep 22Pyc Therapeutics Limited Announces Board ChangesPYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director.
お知らせ • Aug 30PYC Therapeutics Limited Auditor Raises 'Going Concern' DoubtPYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 10PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003.
お知らせ • Feb 18PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 116,651,930 Price\Range: AUD 1.25 Transaction Features: Rights Offering